neutral
15h agoStrong listing pop lifts Corona Remedies as IPO investors log hefty gains
Corona Remedies made an impressive stock market debut on Monday, listing at a sharp premium on both exchanges. The shares opened at ₹1,470 on the NSE and ₹1,452 on the BSE, translating into gains of over 36 percent compared with the IPO price of ₹1,062. The ₹655.68 crore offer-for-sale issue had seen heavy demand across investor categories. Allotted investors earned about ₹20,580 per lot, reflecting strong appetite for the pharmaceutical company’s business profile.
Upstox• By Pooja Kumari
Explore:High Return Equity Mutual Fund
neutral
15h agoStrong listing pop lifts Corona Remedies as IPO investors log hefty gains
Corona Remedies made an impressive stock market debut on Monday, listing at a sharp premium on both exchanges. The shares opened at ₹1,470 on the NSE and ₹1,452 on the BSE, translating into gains of over 36 percent compared with the IPO price of ₹1,062. The ₹655.68 crore offer-for-sale issue had seen heavy demand across investor categories. Allotted investors earned about ₹20,580 per lot, reflecting strong appetite for the pharmaceutical company’s business profile.
Upstox• By Pooja Kumari
Explore:High Return Equity Mutual Fund
1 min read
73 words
Corona Remedies debuted strongly on the bourses with a 36–38 percent premium, delivering over ₹20,000 gains per lot to IPO investors.
Corona Remedies made an impressive stock market debut on Monday, listing at a sharp premium on both exchanges. The shares opened at ₹1,470 on the NSE and ₹1,452 on the BSE, translating into gains of over 36 percent compared with the IPO price of ₹1,062. The ₹655.68 crore offer-for-sale issue had seen heavy demand across investor categories. Allotted investors earned about ₹20,580 per lot, reflecting strong appetite for the pharmaceutical company’s business profile.
Corona Remedies made an impressive stock market debut on Monday, listing at a sharp premium on both exchanges. The shares opened at ₹1,470 on the NSE and ₹1,452 on the BSE, translating into gains of over 36 percent compared with the IPO price of ₹1,062. The ₹655.68 crore offer-for-sale issue had seen heavy demand across investor categories. Allotted investors earned about ₹20,580 per lot, reflecting strong appetite for the pharmaceutical company’s business profile.
Dec 15, 2025 • 06:40